Maud T.
- Country
- France
- Department
- Hematology-oncology department
Research Overview
- Evaluation of HDM201 and Pazopanib in P53 Wild-Type Advanced/Metastatic Soft Tissue Sarcomas
- Phase 1b/2 Evaluation of Efficacy and Safety of GSK5764227 in Adults with Relapsed/Refractory Unresectable Advanced Osteosarcoma or Metastatic Soft‑Tissue Sarcoma
- Randomized Phase II/III Study of Cabozantinib Maintenance Versus Best Supportive Care in Osteosarcoma Patients After First‑Line Chemotherapy (FOSTER‑CabOS)
Data & Insights
Has run more than one trial at 116 of 248 partner sites.
Specializations
Thoracic Oncology
Clinical activity in non-small cell lung cancer, small cell lung cancer, and other advanced thoracic malignancies, with interest in molecularly defined disease such as EGFR-mutated, ALK-positive, ROS1-rearranged, MET-altered, and RET-altered tumors.
- Advanced non-small cell lung cancer
- Extensive-stage small cell lung cancer
- Mesothelioma
- Thoracic tumors with MTAP deletion
Therapeutic focus includes targeted therapy, immune checkpoint inhibition, and biomarker-driven treatment strategies in advanced lung and pleural cancers.
Breast and Gynecologic Oncology
Research involvement spans breast cancer, ovarian cancer, endometrial cancer, and cervical cancer, including hormone receptor-defined and HER2-defined disease, as well as recurrent and metastatic gynecologic malignancies.
- Hormone receptor-positive, HER2-negative breast cancer
- HER2-positive metastatic breast cancer
- High-risk endometrial cancer
- Platinum-resistant ovarian cancer
Therapeutic interests include endocrine therapy, anti-HER2 treatment, PARP inhibition, and immunotherapy across breast and gynecologic cancers.
Sarcoma and Rare Solid Tumors
Clinical research covers soft tissue sarcoma, bone sarcoma, gastrointestinal stromal tumor, and other rare solid tumors, including molecularly selected subtypes such as chondrosarcoma and tenosynovial giant cell tumor.
- Soft tissue sarcoma
- Osteosarcoma
- Gastrointestinal stromal tumor
- Conventional chondrosarcoma
Therapeutic emphasis includes immunotherapy, tyrosine kinase inhibition, and strategies for advanced or unresectable rare mesenchymal tumors.
Genitourinary Oncology
Work in prostate cancer, urothelial carcinoma, and renal cell carcinoma reflects interest in advanced disease, metastatic progression, and biomarker-selected populations.
- Metastatic castration-resistant prostate cancer
- Castration-sensitive prostate cancer
- Urothelial carcinoma
- Renal cell carcinoma
Therapeutic domains include androgen receptor pathway targeting, immune-based treatment, and precision approaches for genomically altered genitourinary tumors.
Precision Oncology and Hematologic Malignancies
Clinical interests extend to molecularly selected solid tumors and hematologic malignancies, with attention to actionable alterations such as KRAS G12C, FGFR, BRAF, NTRK, and MTAP deletion, as well as lymphoma and leukemia.
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Chronic lymphocytic leukemia
- Biomarker-defined advanced solid tumors
Therapeutic focus includes targeted agents, antibody-based therapies, and cellular and immune-directed treatment across both solid and blood cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.